Publications by authors named "Jennifer Benselin"
Article Synopsis
- Hepatocellular carcinoma (HCC) is a type of liver cancer that is becoming more common and is the fourth leading cause of cancer deaths worldwide, especially in people with liver cirrhosis.
- The study aims to find early signs of HCC in patients with cirrhosis by using better tests and involves tracking around 3,000 patients over several years.
- The research is approved by ethics boards, and the findings will be shared publicly to help improve cancer detection and treatment.
Article Synopsis
- The study aimed to assess mortality rates in patients treated for hepatitis C using modern interferon-free, direct-acting antivirals and compare them to the general populace.
- A total of 21,790 patients treated between 2014 and 2019 were analyzed, categorized by liver disease severity, with follow-up ending either at death or by the end of 2019.
- Results showed a 7% mortality rate during follow-up, with deaths primarily from drug-related issues, liver failure, and liver cancer, and overall mortality rates significantly exceeded those of the general population, especially for patients with more advanced liver disease.
Background: Previous studies show the uptake of biannual ultrasound (US) surveillance in patients with cirrhosis is suboptimal. Here, our goal was to understand in broader terms how surveillance is being delivered to cirrhosis patients with cured hepatitis C in the UK.
Methods: Hepatitis C cirrhosis patients achieving a sustained viral response (SVR) to antiviral therapies were identified from the national Hepatitis-C-Research-UK resource.
Introduction: Risk-stratifying patients with hepatitis C virus (HCV) cirrhosis according to medium-term prognosis will inform clinical decision-making. It is unclear which biomarkers/models are optimal for this purpose. We quantified the discriminative ability of 14 diverse biomarkers for prognosis prediction over a 4-year time.
View Article and Find Full Text PDFThe host genetic background for hepatocellular carcinoma (HCC) is incompletely understood. We aimed to determine if four germline genetic polymorphisms, rs429358 in apolipoprotein E (APOE), rs2642438 in mitochondrial amidoxime reducing component 1 (MARC1), rs2792751 in glycerol-3-phosphate acyltransferase (GPAM), and rs187429064 in transmembrane 6 superfamily member 2 (TM6SF2), previously associated with progressive alcohol-related and nonalcoholic fatty liver disease, are also associated with HCC. Four HCC case-control data sets were constructed, including two mixed etiology data sets (UK Biobank and FinnGen); one hepatitis C virus (HCV) cohort (STOP-HCV), and one alcohol-related HCC cohort (Dresden HCC).
View Article and Find Full Text PDFBackground & Aims: Hepatocellular carcinoma (HCC) prediction models can inform clinical decisions about HCC screening provided their predictions are robust. We conducted an external validation of 6 HCC prediction models for UK patients with cirrhosis and a HCV virological cure.
Methods: Patients with cirrhosis and cured HCV were identified from the Scotland HCV clinical database (N = 2,139) and the STratified medicine to Optimise Treatment of Hepatitis C Virus (STOP-HCV) study (N = 606).
Sustained viral response (SVR) rates for direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection routinely exceed 95%. However, a small number of patients require retreatment. Sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) is a potent DAA combination primarily used for the retreatment of patients who failed by DAA therapies.
View Article and Find Full Text PDFBackground & Aims: Chronic hepatitis C virus (HCV) infection is a global health burden. Although HCV infection rarely contributes to morbidity during childhood, most HCV-infected children develop chronic HCV with a lifetime risk of liver disease. Little is known about the development of long-term liver disease and the effect of treatment in patients infected with HCV in childhood.
View Article and Find Full Text PDF